{
    "clinical_study": {
        "@rank": "26725", 
        "arm_group": [
            {
                "arm_group_label": "Catheter-based renal denervation", 
                "arm_group_type": "Experimental", 
                "description": "One procedure will be performed using one of the CE-marked devices for renal denervation:\nDevice:   Renal denervation with Symplicity Flex Medtronic/Ardian Device:   Renal denervation with EnligHTN St. Jude Medical Device:   Renal denervation with Paradise Recor Device:   Renal denervation with V2 Vessix"
            }, 
            {
                "arm_group_label": "Medical therapy", 
                "arm_group_type": "No Intervention", 
                "description": "Best medical therapy using guideline recommended drugs in each disease state."
            }
        ], 
        "brief_summary": {
            "textblock": "The study is aiming to document the long-term safety and effectiveness of renal denervation\n      in patients with hypertension and other diseases characterized by elevated sympathetic\n      drive. Catheter-based renal denervation will be performed using CE marked, percutaneous,\n      systems."
        }, 
        "brief_title": "Influence of Catheter-based Renal Denervation in Diseases With Increased Sympathetic Activity", 
        "completion_date": {
            "#text": "January 2021", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hypertension", 
            "Heart Failure", 
            "Chronic Kidney Disease", 
            "Diabetes", 
            "Heart Rhythm Disorders"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Hypertension", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Inclusion Criteria\n\n        1. Individual is 18 years of age.\n\n        2. Individual agrees to have all procedures performed, and is competent and willing to\n           provide written, informed consent to participate in the registry.\n\n        3. Patient scheduled for renal sympathetic denervation using market-released device.\n\n      Exclusion Criteria\n\n        1. In the eyes of the treating physician, the renal artery anatomy would interfere with\n           safe cannulation of the renal artery or meets local standards for surgical repair.\n\n        2. Individual has any serious medical condition, which in the opinion of the treating\n           physician may adversely affect the safety and/or effectiveness of the participant\n           (i.e., patients with clinically significant peripheral vascular disease, abdominal\n           aortic aneurysm, bleeding disorders such as thrombocytopenia, hemophilia, significant\n           anemia, etc.)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          1. Individual is 18 years of age.\n\n          2. Individual agrees to have all procedures performed, and is competent and willing to\n             provide written, informed consent to participate in the registry.\n\n          3. Patient scheduled for renal sympathetic denervation using market-released device.\n\n        Exclusion Criteria\n\n          1. In the eyes of the treating physician, the renal artery anatomy would interfere with\n             safe cannulation of the renal artery or meets local standards for surgical repair.\n\n          2. Individual has any serious medical condition, which in the opinion of the treating\n             physician may adversely affect the safety and/or effectiveness of the participant\n             (i.e., patients with clinically significant peripheral vascular disease, abdominal\n             aortic aneurysm, bleeding disorders such as thrombocytopenia, hemophilia, significant\n             anemia, etc.)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01888315", 
            "org_study_id": "Symplicity Extension"
        }, 
        "intervention": [
            {
                "arm_group_label": "Catheter-based renal denervation", 
                "description": "Renal denervation using CE-marked devices will be performed according to best medical practice.", 
                "intervention_name": "Renal denervation with Symplicity Flex Medtronic/Ardian", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Catheter-based renal denervation", 
                "description": "Renal denervation using CE-marked devices will be performed according to best medical practice.", 
                "intervention_name": "Renal denervation with EnligHTN St. Jude Medical", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Catheter-based renal denervation", 
                "description": "Renal denervation using CE-marked devices will be performed according to best medical practice.", 
                "intervention_name": "Renal denervation with Paradise Recor", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Catheter-based renal denervation", 
                "description": "Renal denervation using CE-marked devices will be performed according to best medical practice.", 
                "intervention_name": "Renal denervation with V2 Vessix", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hypertension", 
            "Heart Failure", 
            "Sympathetic activity"
        ], 
        "lastchanged_date": "June 24, 2013", 
        "location": {
            "contact": {
                "last_name": "Michael B\u00f6hm, MD"
            }, 
            "contact_backup": {
                "last_name": "Felix Mahfoud, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Homburg/Saar", 
                    "country": "Germany", 
                    "zip": "66421"
                }, 
                "name": "University Hospital Saarland"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety and Efficacy Study Investigating the Effects of Catheter-based Renal Denervation on Different Organ Systems in Patients With Increased Sympathetic Activity", 
        "overall_contact": {
            "email": "felix.mahfoud@uks.eu", 
            "last_name": "Felix Mahfoud, MD", 
            "phone": "+4968411621346"
        }, 
        "overall_contact_backup": {
            "email": "michael.boehm@uks.eu", 
            "last_name": "Michael B\u00f6hm, MD", 
            "phone": "+4968411623372"
        }, 
        "overall_official": [
            {
                "affiliation": "University Hospital, Saarland", 
                "last_name": "Felix Mahfoud, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "University Hospital, Saarland", 
                "last_name": "Michael B\u00f6hm, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2021", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Effect on blood pressure including office, ABPM, and home-based measurements.\nNumber of adverse events (death, stroke, myocardial infarction, new dialysis, and congestive heart failure).\nChanges of antihypertensive medications.\nEffects on renal function assessed with glomerular filtration rate.\nRenovascular safety (renal artery stenosis) assessed by duplex ultrasound.", 
            "measure": "Safety and efficacy of renal denervation", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01888315"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Myocardial function and geometry using echo and MRI.\nHeart rate changes and arrhythmias.\nGlucose metabolism and insulin resistance (fasting and during oGTT).\nHospitalization rates (eg. hypertensive emergencies, heart failure, etc).", 
                "measure": "Effect of renal denervation on different organ systems.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 months"
            }, 
            {
                "description": "Effect on blood pressure including office, ABPM, and home-based measurements.\nNumber of adverse events (death, stroke, myocardial infarction, new dialysis, and congestive heart failure).\nChanges of antihypertensive medications.\nEffects on renal function assessed with glomerular filtration rate.\nRenovascular safety (renal artery stenosis) assessed by duplex ultrasound.", 
                "measure": "Safety and efficacy of renal denervation", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 3, 12, 18, 24, 30, 36, 42, 48, 54, 60 months"
            }
        ], 
        "source": "University Hospital, Saarland", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Saarland", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}